StemCells, Inc. Added to Russell Microcap Index

StemCells, Inc. Added to Russell Microcap Index

NEWARK, Calif., July 1, 2013 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM)
today announced its addition to the Russell Microcap Index following Russell
Investments' reconstitution of its comprehensive set of U.S. and global equity
indexes. The Russell Microcap Index measures the performance of the microcap
segment of the U.S. equity market.Microcap stocks make up less than 3 percent
of the U.S. equity market (by market cap) and consist of the smallest 1,000
securities in the small-cap Russell 2000® Index, plus the next smallest
eligible securities by market cap. 

The Russell Microcap Index is constructed to provide a comprehensive and
unbiased barometer for the microcap segment trading on national exchanges,
while excluding lesser-regulated OTC bulletin board securities and pink-sheet
stocks due to their failure to meet national exchange listing requirements.
The Russell Microcap is completely reconstituted annually to ensure larger
stocks do not distort performance and characteristics of the true microcap
opportunity set.

About StemCells, Inc.

StemCells, Inc. is engaged in the research, development, and commercialization
of cell-based therapeutics and tools for use in stem cell-based research and
drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC®
cells (purified human neural stem cells), is currently in development as a
potential treatment for a broad range of central nervous system disorders. In
a PhaseI clinical trial in Pelizaeus-Merzbacher disease (PMD), a fatal
myelination disorder in children, the Company has shown preliminary evidence
of progressive and durable donor-derived myelination in all four patients
transplanted with HuCNS-SC cells.The Company is also conducting a Phase I/II
clinical trial in chronic spinal cord injury in Switzerland and Canada and has
reported positive interim data for the first three patients.The Company has
also initiated a Phase I/II clinical trial in dry age-related macular
degeneration (AMD), and is pursuing preclinical studies in Alzheimer's
disease. StemCells also markets stem cell research products, including media
and reagents, under the SC Proven® brand.Further information about StemCells
is available at http://www.stemcellsinc.com.

Apart from statements of historical fact, the text of this press release
constitutes forward-looking statements within the meaning of the Securities
Act of 1933, as amended, and the Securities Exchange Act of 1934, as amended,
and is subject to the safe harbors created therein.These forward-looking
statements speak only as of the date of this news release. The Company does
not undertake to update any of these forward-looking statements to reflect
events or circumstances that occur after the date hereof. Such statements
reflect management's current views and are based on certain assumptions that
may or may not ultimately prove valid. The Company's actual results may vary
materially from those contemplated in such forward-looking statements due to
risks and uncertainties to which the Company is subject, including the fact
that additional trials will be required to demonstrate the safety and efficacy
of the Company's HuCNS-SC cells for the treatment of any disease or disorder;
uncertainty as to whether the FDA, Health Canada or other applicable
regulatory agencies will permit the Company to continue clinical testing in
spinal cord injury, AMD or in future clinical trials of proposed therapies for
other diseases or conditions; uncertainties regarding the Company's ability to
obtain the increased capital resources needed to continue its current and
planned research and development operations; and other factors that are
described under the heading "Risk Factors" in the Company's Annual Report on
Form 10-K for the year ended December 31, 2012, and in its subsequent reports
on Form 10-Q and Form 8-K.

CONTACT: Rodney Young
         StemCells, Inc.
         Chief Financial Officer
         (510) 456-4128
        
         Ian Stone
         Russo Partners
         (619) 308-6541

company logo
 
Press spacebar to pause and continue. Press esc to stop.